Ibutamoren / MK-677 is categorized as Non-peptide ghrelin receptor agonist; its regulatory category in this atlas is Non-peptide comparison item.
Human ObservationalPEPTIDE DOSSIER
Ibutamoren / MK-677
Ibutamoren / MK-677 is classified as Non-peptide ghrelin receptor agonist. This profile separates what is known from source-linked evidence, what remains uncertain, safety considerations, and the US regulatory context.
MK-677Ibutamoren mesylateNot a peptide
Executive Summary
What is it?
Ibutamoren / MK-677 is a profile in the atlas because people search for it as a peptide, peptide medicine, peptide-like hormone, supplement ingredient, cosmetic peptide, or nearby comparison item. The key question is not just what it is called, but whether a specific product has reliable evidence, clear safety information, and a verified regulatory pathway.
What is it used or studied for?
Ibutamoren / MK-677 is commonly searched in connection with growth hormone pathways. Some uses may be approved for specific products, while others may only be studied, speculative, cosmetic, supplement-related, or unsupported.
How it interacts with the body
In simple terms, Ibutamoren / MK-677 is discussed through Oral ghrelin receptor agonism; included as a non-peptide comparison item. That means the profile focuses on the body signal, receptor, or pathway it is believed or known to affect, while separating proven labeled uses from research-only claims.
What we know
- - Ibutamoren / MK-677 is categorized as Non-peptide ghrelin receptor agonist.
- - Ibutamoren / MK-677 currently has evidence grade C in this atlas.
- - Regulatory category: Non-peptide comparison item.
What remains uncertain
- - Product-specific legality, quality, and labeling can vary by jurisdiction and supplier.
- - Long-term safety and real-world adverse-event patterns may be incomplete outside approved product contexts.
- - Claims not tied to FDA labeling or human trials should be treated cautiously.
Non-technical takeaway
Ibutamoren / MK-677 should be read through three filters: what the evidence says, what the regulatory status actually means, and what safety uncertainties remain.
People usually search Ibutamoren / MK-677 to understand potential uses, how it works in the body, whether it is approved, and what safety concerns or evidence gaps matter.
Key safety considerations
Safety context for Ibutamoren / MK-677 should be interpreted through product-specific labels or the limits of available research. Non-approved products should not be treated as safe for human use.
Chemical and Scientific Profile
- Peptide type
- non-peptide comparison item
- Sequence
- Unknown
- Formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- 178024
- Targets
- Unknown
- Routes studied
- not fully characterized
Molecular visualization placeholder
Mechanism of Action
Explain like I’m new
Ibutamoren / MK-677 is discussed through the pathway: Oral ghrelin receptor agonism; included as a non-peptide comparison item. The plain-language interpretation should stay anchored to verified evidence and labeled uses.
Advanced scientific view
Advanced view: Oral ghrelin receptor agonism; included as a non-peptide comparison item. Receptor/pathway details require claim-level citations before being treated as clinically meaningful.
Oral ghrelin receptor agonism; included as a non-peptide comparison item
Benefits and Claims
Promising
Preclinical Only
Ibutamoren / MK-677 should be interpreted through source-linked evidence, not marketing claims or protocol claims.
Human ObservationalUnsupported / Safety Claim
Ibutamoren / MK-677 is not presented here with an approved human self-administration protocol; safety and legal status require caution.
UnsupportedEvidence Dashboard
C
Evidence grade
not yet fully characterized
Human data
not yet fully characterized
Animal data
mixed or limited
Citation quality
source search placeholder
Research tracker for Ibutamoren / MK-677
- Population
- Not yet curated from a specific trial.
- Intervention
- Ibutamoren / MK-677
- Comparator
- Not yet curated.
- Outcomes
- Research outcomes require manual source review.
- Limitations
- This study card is a seed-level summary and should be replaced by full PICO extraction during editorial review.
- Funding/conflict
- Funding and conflict notes require editorial extraction from the full source.
Dosing and Administration Guardrails
No FDA-approved human dosing protocol is provided here. This profile does not include self-administration, injection, or reconstitution instructions.
This site does not provide personalized protocols, DIY preparation, injection, reconstitution, or self-administration instructions.
Safety Section
Common side effects
- - not well characterized in this seed
Serious warnings
- - unknown long-term safety or product-specific warning gaps
Contraindications
- - not fully characterized; consult product-specific labeling or clinician
Interactions
- - not fully characterized
Regulatory and Sport Status
Comparisons
Compare evidence, regulatory status, route, and safety context before treating two compounds as similar.
FAQs
Is Ibutamoren / MK-677 FDA-approved?
This seed does not verify Ibutamoren / MK-677 as FDA-approved for general human use. The profile is educational and should not be read as medical advice or a protocol.
What is the main evidence caveat for Ibutamoren / MK-677?
Ibutamoren / MK-677 is categorized as Non-peptide comparison item. Evidence strength depends on whether a claim comes from FDA labeling, human trials, animal studies, in vitro work, or unsupported marketing.
Does this page provide dosing instructions for Ibutamoren / MK-677?
No. For non-approved compounds, this site explicitly avoids self-administration, injection, and dosing protocols.